文献速递类风湿关节炎

泼尼松使用、疾病活动度与早期类风湿关节炎患者高血糖和糖尿病的发生:BeSt研究10年亚组分析

Prednisone use, disease activity and the occurrence of hyperglycaemia and diabetes in patients with early rheumatoid arthritis: a 10-year subanalysis of the BeSt study.
PubMed 文献 · RMD Open · 2024-04-30

该研究纳入504例非糖尿病早期类风湿关节炎患者,随机分入4个以疾病活动度评分(DAS)为导向的治疗组并随访10年。校正多重检验后,泼尼松使用与高血糖或糖尿病发生无关;DAS每升高1分与糖尿病发生显著相关(HR 1.802,95%CI 1.284至2.529)。

要点

  • 504例中31例(6.2%)随访期间发生糖尿病,其中11例(35%)曾接受泼尼松治疗。
  • 校正多重检验后,泼尼松使用与高血糖或糖尿病发生无关。
  • DAS每升高1分,糖尿病发生风险HR 1.802(95%CI 1.284至2.529)。

核心结论

  • 在非糖尿病早期类风湿关节炎患者中,泼尼松使用与高血糖或糖尿病发生无关,但高DAS增加糖尿病风险。
  • 泼尼松使用相关的潜在风险可能被其对DAS的效应所抵消。

研究设计与样本

  • BeSt研究(荷兰治疗策略研究)的10年亚组分析,纳入504例非糖尿病早期类风湿关节炎患者,随机分入4个以DAS为导向的治疗组。
  • 采用线性及逻辑混合效应回归模型评估DAS和泼尼松使用与血糖水平及高血糖发生的关联,采用Cox回归分析糖尿病发生,并在首次发生高血糖的患者中进行敏感性分析。

主要发现

  • 504例患者中31例(6.2%)随访期间发生糖尿病,平均年龄54岁,其中11例(35%)曾接受泼尼松治疗。
  • 校正多重检验后,泼尼松使用与高血糖或糖尿病发生无关(主分析及敏感性分析)。
  • 主分析中,DAS与糖尿病发生显著相关(每升高1分HR 1.802,95%CI 1.284至2.529),但与血糖水平及高血糖无显著关联。
  • 在既往发生高血糖的患者中,DAS与血糖水平、高血糖复发及糖尿病相关。

关键数值与推荐

  • DAS每升高1分,糖尿病发生HR 1.802(95%CI 1.284至2.529)。
  • 504例中31例(6.2%)发生糖尿病,其中11例(35%)曾接受泼尼松治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess whether prednisone use and/or disease activity score (DAS) are associated with the development of hyperglycaemia and diabetes in rheumatoid arthritis (RA). METHODS: We included 504 non-diabetic early RA patients from the BeSt study (Dutch acronym for treatment strategies). Patients were randomised to four DAS-steered treatment arms and followed for 10 years. The associations between DAS and prednisone use with glucose levels and the occurrence of hyperglycaemia over time were assessed with linear and logistic mixed effects regression models. Development of diabetes was analysed with Cox regression. Sensitivity analyses were performed in patients who had a first episode of hyperglycaemia. RESULTS: 31 of 504 patients (6.2%) with a mean age of 54 years developed diabetes during follow-up; 11 of these (35%) had received prior treatment with prednisone. Prednisone use was not associated with development of hyperglycaemia or diabetes after correction for multiple testing in main or sensitivity analyses. In the main analyses, DAS was significantly associated with development of diabetes (HR 1.802 per 1 point DAS increase, 95% CI 1.284 to 2.529) but not with glucose levels nor hyperglycaemia. In patients with previous hyperglycaemia, DAS was associated with glucose levels, recurrence of hyperglycaemia and diabetes. CONCLUSIONS: In non-diabetic early RA patients, the use of prednisone was not associated with developing hyperglycaemia or diabetes. However, high DAS increased the risk of diabetes. Potential risks associated with prednisone use may have been mitigated by its effect on DAS.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. van der Pol JA, Allaart CF, Lems W, et al. Prednisone use, disease activity and the occurrence of hyperglycaemia and diabetes in patients with early rheumatoid arthritis: a 10-year subanalysis of the BeSt study. RMD Open. 2024. PMID: 38688692. doi:10.1136/rmdopen-2024-004246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。